Short-and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice
Objective To estimate the occurrence and relative risks of first-ever-incident non-cutaneous
cancer overall and for 16 sites in patients with RA treated with biologic and targeted …
cancer overall and for 16 sites in patients with RA treated with biologic and targeted …
Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study
Objective Assess cancer risks with Janus kinase inhibitors (JAKi) versus biological disease-
modifying antirheumatic drugs (bDMARDs) in clinical practice. Methods Cohort study of …
modifying antirheumatic drugs (bDMARDs) in clinical practice. Methods Cohort study of …